Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial

Jung Min Ahn, Duk Woo Park, Young Hak Kim, Haegeun Song, Young Rak Cho, Won Jang Kim, Jong Young Lee, Soo Jin Kang, Seung Whan Lee, Cheol Whan Lee, Seong Wook Park, Sung Cheol Yun, Seungbong Han, Sung Yun Lee, Bong Ki Lee, Jang Hyun Cho, Tae Hyun Yang, Nae Hee Lee, Joo Young Yang, Jong Seon ParkWon Yong Shin, Moo Hyun Kim, Jang Ho Bae, Myeong Kon Kim, Junghan Yoon, Seung Jung Park

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo stent-based coronary interventions. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and sirolimus-eluting stents (SES) for patients with de novo long coronary lesions. Methods and Results: This randomized, multicenter, prospective trial, called the Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV (LONG-DES IV) trial, compared long R-ZES and SES in 500 patients with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-segment late luminal loss at 9-month angiographic follow-up. The baseline characteristics were not different between R-ZES and SES groups, including lesion lengths (32.4±13.5 mm versus 31.0±13.5 mm, P=0.27). At 9-month angiographic follow-up, the R-ZES was noninferior to the SES with respect to in-segment late luminal loss, the primary study end point (0.14±0.38 mm versus 0.12±0.43 mm, P for noninferiority=0.03, P for superiority=0.68). In addition, in-stent late luminal loss (0.26±0.36 mm versus 0.24±0.42 mm, P=0.78) and the rates of in-segment (5.2% versus 7.2%, P=0.44) and in-stent (4.0% versus 6.0%, P=0.41) binary restenosis were not significantly different between the 2 groups. There were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, stent thrombosis, target-lesion revascularization, and composite outcomes). Conclusions: For patients with de novo long coronary artery disease, R-ZES implantation showed noninferior angiographic outcomes as compared with SES implantation.

Original languageEnglish
Pages (from-to)633-640
Number of pages8
JournalCirculation: Cardiovascular Interventions
Volume5
Issue number5
DOIs
Publication statusPublished - 2012 Oct

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial'. Together they form a unique fingerprint.

  • Cite this

    Ahn, J. M., Park, D. W., Kim, Y. H., Song, H., Cho, Y. R., Kim, W. J., Lee, J. Y., Kang, S. J., Lee, S. W., Lee, C. W., Park, S. W., Yun, S. C., Han, S., Lee, S. Y., Lee, B. K., Cho, J. H., Yang, T. H., Lee, N. H., Yang, J. Y., ... Park, S. J. (2012). Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial. Circulation: Cardiovascular Interventions, 5(5), 633-640. https://doi.org/10.1161/CIRCINTERVENTIONS.111.965673